

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. **(Original)** A method for the preparation of human, humanized or chimaeric antibodies or polypeptides comprising Fc region of human IgG, said antibodies or polypeptides having different binding profiles, wherein said method comprises the steps consisting of:

- a) providing candidate human, humanized or chimaeric antibodies or polypeptides comprising Fc region of human IgG produced naturally by or following transfection with a vector comprising the coding sequence for said antibody or polypeptide of cells from animal cell lines comprising hybridoma, heterohybridoma, EBV-transformed human B cell lines or from eukaryotic microorganisms,
- b) testing the binding of said antibodies or polypeptides on Fcgamma receptors including FcgammaRIIIA, FcgammaRIIA and FcgammaRIIB,
- c) selecting antibodies or polypeptides which:
  - i) bind to both FcgammaRIIIA, FcgammaRIIA and FcgammaRIIB, or
  - ii) bind to both FcgammaRIIA and FcgammaRIIB but do not bind or bind only weakly to FcgammaRIIIA, or
  - iii) do not bind or bind only weakly to both FcgammaRIIIA, FcgammaRIIA and FcgammaRIIB.

2. **(Original)** A method according to claim 1, wherein said antibodies or polypeptides selected in the step c) iO are produced by cells from lymphoid cell lines or lymphoid-derived cell lines or hybridomas or from epithelial kidney cell lines, said antibodies or polypeptides selected in the step c) ii) are produced by cells from non-lymphoid cell lines and said antibodies or polypeptides selected in the step c) iii) are produced by cells from an heterohybridoma fused to cells from an EBV-transformed cell line or to B lymphocytes from human donors.

3.     **(Original)** A method according to claim 2, wherein said lymphoid-derived cell lines are rat myeloma cell lines or the hybridoma YB2/0 cell line (ATCC number CRL-1662) or cell lines derived thereof, and/or the epithelial kidney cell line is VERO (ATCC number CCL-81) or cell lines derived thereof, and/or the non-lymphoid cell line is CHO (ATCC number CCL-61) or cell lines derived thereof and/or said heterohybridoma is K6H6B5 (ATCC number CRL-I823) or cell lines derived thereof.

4.-47. **(Cancelled)**